Introducing
Genomic Control

Omega Therapeutics is creating transformative medicines that unleash the human genome's native capacity to cure disease.

CONTROLLING INSULATED GENOMIC DOMAINS (IGDs), THE GENOMSTATS™ OF THE HUMAN GENOME

At Omega Therapeutics, our work explores the new science of genomic activation to cure diseases. Many health conditions, particularly complex diseases, are the result of malfunctions in the regulation of gene expression. Rather than modifying genetic code by changing nucleic acid sequences, Omega Therapeutics is focused on directing the human genome to treat and potentially cure disease through our proprietary platform that precisely tunes IGDs, which are fundamental regulators (the “GenomStats™”) of the human genome.

IGDs are three-dimensional, closed-loop structures of DNA that control genomic activity, resulting from tertiary folds of the DNA. These structures appear as loops to encompass one or more genes and their associated regulatory elements. Approximately 15,000 of these novel therapeutic targets comprise 70% of the human genome. Our goal is to unlock the native capacity of the genome to treat and potentially cure disease.

INSULATED GENOMIC DOMAINS (IGDs) ARE NOVEL THERAPEUTIC TARGETS THAT PRESENT AN UNPRECEDENTED OPPORTUNITY TO CONTROL GENOME ACTIVATION.

AN UPDATED VIEW OF THE CENTRAL DOGMA — ORGANIZATION OF THE DNA AND GENOMIC ACTIVATION

We are interrogating the central dogma to discover new ways of treating and potentially curing disease.
DNA and Genomic activation